StockData
Core Scientific, Inc./tx logo

Core Scientific, Inc./tx (CORZ) stock analysis

CORZNasdaqFinance ServicesFiscal year ends December 31Also trades as CORZR, CORZW, CORZZ
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 4/30194% above fair value
$14.52+0.14 (+0.97%)

Close on Nov 13, 2026Market cap $4.67BP/E –Yield –

StockData Score

Prices as of Nov 13, 2026How the score works

Value0Growth2Performance2Health0Dividend0

Weak4 of 30 checks passed

Core Scientific passes 4 of the 30 checks behind our score; 17 could not be run for lack of data and count as not passed. Each dot in the shape is one check — hover it for the numbers.

Valuation
0/6
Growth
2/6
Past performance
2/6
Financial health
0/6
Dividend
0/6

What stands out

  • Growing faster than the industry

    Revenue grew 77.2% over the last twelve months; the Finance services median is 9.8%.

  • Gross margin improving

    Gross margin was 41.2% over the last twelve months, against 6.6% a year earlier.

  • Net margin above its 5-year average

    Net margin was -18.3% over the last twelve months, against a 5-year average of -150%.

  • Net margin above the industry

    Core Scientific's net margin of -18.3% is above the Finance services median of -64.5%.

What to watch

  • Margin of safety under 20%

    The price is 194% above fair value, so there is no margin of safety.

  • Trading above fair value

    The share price of $14.52 is above our fair value estimate of $4.93.

  • Return on capital under 10%

    Return on invested capital was -39.0%, below the 10% that usually covers the cost of capital.

  • Revenue growing under 10% a year

    Revenue grew -20.7% a year over the last three fiscal years, short of the 10% we look for.

Valuation0/6

  • P/E against its history

    Not enough price and earnings history to compare.

  • P/E against the industry

    Needs positive earnings and enough profitable companies in the industry.

  • EV/EBITDA against its history

    Needs positive EBITDA and price history.

  • P/S above the industry

    Core Scientific's price-to-sales of 7.88 is above the Finance services median of 3.29 (book value is negative, so we use sales).

  • Trading above fair value

    The share price of $14.52 is above our fair value estimate of $4.93.

  • Margin of safety under 20%

    The price is 194% above fair value, so there is no margin of safety.

Growth2/6

  • Revenue growing under 10% a year

    Revenue grew -20.7% a year over the last three fiscal years, short of the 10% we look for.

  • EPS growth over 3 years

    Needs positive EPS three years ago and today.

  • Earnings acceleration

    Needs positive net income now, a year ago and five years ago.

  • Growing faster than the industry

    Revenue grew 77.2% over the last twelve months; the Finance services median is 9.8%.

  • Company guidance

    No outlook found in earnings releases from the last twelve months.

  • Gross margin improving

    Gross margin was 41.2% over the last twelve months, against 6.6% a year earlier.

Past performance2/6

  • Return on equity

    Needs positive equity and five years of results.

  • Return on capital under 10%

    Return on invested capital was -39.0%, below the 10% that usually covers the cost of capital.

  • Return on equity against the industry

    Needs positive equity.

  • Earnings over 5 years

    Needs positive net income five years ago and in the latest year.

  • Net margin above its 5-year average

    Net margin was -18.3% over the last twelve months, against a 5-year average of -150%.

  • Net margin above the industry

    Core Scientific's net margin of -18.3% is above the Finance services median of -64.5%.

Financial health0/6

  • Debt level

    Needs debt and equity figures.

  • Debt trend

    Needs a balance sheet from five years ago with positive equity.

  • Debt not well covered by cash flow

    Operating cash flow over the last twelve months equals 10.5% of total debt; we look for at least 20%.

  • Interest coverage

    Interest expense is not reported separately.

  • Short-term assets don't cover short-term debts

    Current assets are 0.67 times current liabilities.

  • Elevated bankruptcy risk

    The Altman Z-score is -0.94; above 3 is the safe zone and below 1.8 the distress zone.

Dividend0/6

  • No dividend

    Core Scientific has not paid a dividend in the last twelve months.

  • Yield against Treasuries

    No dividend.

  • Yield against the market

    No dividend.

  • Dividend stability

    No dividend.

  • Earnings cover

    No dividend.

  • Cash-flow cover

    No dividend.

Scores of similar companies

Fair value

How we estimate it

Our estimate per share

$4.93

The share price is 194% above this estimate.

20%+ below
Near fair value
20%+ above
$14.52Price$4.93Fair value
MethodMultiple usedOwn 5Y medianIndustry medianValue per shareWeight
P/S5.0×8.9×3.3×$9.1540%
Earnings power10.1% cost of equity––$2.1260%
Fair value$4.93100%

Valuation over time

Using the earnings and balance sheet published at each date, not today's.

  • EV/EBITDA at month end
  • Finance services median 13.5

An estimate from reported numbers and market multiples, not a price target or investment advice. It can be far off for companies whose profits are about to change sharply.

Market risk

From the past year of daily prices.

Liquidity

Low risk

Average value traded per day
$238.33M
Value traded per 1% price move
$52.13M

Downside

High risk

Typical loss in a bad month
26.8%
Volatility (annualized)
76%
Sharpe ratio, 1 year
-0.22
Beta to the S&P 500 (5Y)
–

Typical bad-month loss, week by week

25%: high

Margins

Share of revenue, fiscal years 2019 to 2025

Gross margin

11.9%−3.7 pts over 5 years

Operating margin

-77.0%−66.5 pts over 5 years

Net margin

-90.5%−70.2 pts over 5 years

See a number that looks wrong?